

1. Zhao, L., Wang, Q., Zhao, D., Zhou, J., Jiang, W., Ye, J., Wang, S., & Shen, L. (2021). Genetic mutations associated with sensitivity to neoadjuvant chemotherapy in metastatic colon cancer: A case report and literature review. *World Journal of Clinical Cases, 9*(24), 7099.
<https://doi.org/10.12998/wjcc.v9.i24.7099>
2. Housman, G., Byler, S., Heerboth, S., Lapinska, K., Longacre, M., Snyder, N., & Sarkar, S. (2014). Drug resistance in cancer: An overview. *Cancers, 6*(3), 1769.
<https://doi.org/10.3390/cancers6031769Drug>
3. National Cancer Institute. (n.d.). Why do cancer treatments stop working? *NCI*. Retrieved from <https://www.cancer.gov>
4. Ramos, A., Sadeghi, S., & Tabatabaeian, H. (2021). Battling chemoresistance in cancer: Root causes and strategies to uproot them. *International Journal of Molecular Sciences, 22*(17), 9451.
<https://doi.org/10.3390/ijms22179451>
5. Medical News Today. (n.d.). Why some cancer tumours can become resistant to chemotherapy. Retrieved from <https://www.medicalnewstoday.com>
6. National Institutes of Health. (n.d.). Battling chemoresistance in cancer: Root causes and strategies. Retrieved from <https://pmc.ncbi.nlm.nih.gov>
7. Mesothelioma Center. (n.d.). High cost of cancer treatment: Chemotherapy & other costs. Retrieved from <https://www.asbestos.com>
8. The ASCO Post. (2018). Expensive cancer drugs don't work if patients can't afford them. Retrieved from <https://ascopost.com>

9. Alberta Health Services. (n.d.). Community cancer supportive care resources. Retrieved from <https://www.albertahealthservices.ca>
10. Harvard T.H. Chan School of Public Health. (n.d.). Making health care more affordable. Retrieved from <https://hsph.harvard.edu>
11. Precursive. (n.d.). Cost-effectiveness vs cost-efficient: The difference. Retrieved from <https://www.precursive.com>
12. Charlotte Cancer Treatment. (n.d.). The cost of cancer treatment. Retrieved from <https://treatcancer.com>
13. Canadian Partnership Against Cancer. (n.d.). Evaluating cost-effectiveness: An essential part of new cancer treatments. Retrieved from <https://www.partnershipagainstcancer.ca>
14. Canadian Cancer Society. (n.d.). How cancer starts, grows, and spreads. Retrieved from <https://cancer.ca>
15. National Cancer Institute. (n.d.). Chemotherapy to treat cancer. *NCI*. Retrieved from <https://www.cancer.gov>
16. FutureLearn. (n.d.). Intrinsic resistance. Retrieved from <https://www.futurelearn.com>
17. American Cancer Society. (n.d.). CAR T-cell therapy and its side effects. Retrieved from <https://www.cancer.org>
18. National Institutes of Health. (n.d.). An overview of the antimicrobial resistance mechanisms of... Retrieved from <https://pmc.ncbi.nlm.nih.gov>
19. MedlinePlus. (n.d.). Carcinoid tumours. Retrieved from <https://medlineplus.gov>
20. Mayo Clinic. (n.d.). Carcinoid tumours - Symptoms and causes. Retrieved from <https://www.mayoclinic.org>
21. National Cancer Institute. (n.d.). Definition of drug resistance. Retrieved from <https://www.cancer.gov>

22. National Institutes of Health. (n.d.). Cancer evolution: A multifaceted affair. Retrieved from <https://pmc.ncbi.nlm.nih.gov>
23. World Health Organization. (n.d.). Global cancer burden growing, amidst mounting need for... Retrieved from <https://www.who.int>
24. Cancer Council. (n.d.). Myeloma | Causes, symptoms & treatments. Retrieved from <https://www.cancer.org>
24. National Cancer Institute. (n.d.). *New principle of chemotherapy resistance*. Retrieved from <https://www.cancer.gov>
25. Ramos, A., Sadeghi, S., & Tabatabaeian, H. (2021). Battling Chemoresistance in Cancer: Root Causes and Strategies to Uproot Them. *International Journal of Molecular Sciences*, 22(17), 9451. [Battling Chemoresistance in Cancer: Root Causes and ...National Institutes of Health \(NIH\) \(.gov\)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8430957)
[https://pmc.ncbi.nlm.nih.gov › articles › PMC8430957](https://pmc.ncbi.nlm.nih.gov/articles/PMC8430957)
26. Ajith, A. K., Subramani, S., Manickam, A. H., & Ramasamy, S. (2021). Chemotherapeutic Resistance Genes of Breast Cancer Patients - An Overview. *Advanced Pharmaceutical Bulletin*, 12(4), 649. [Chemotherapeutic Resistance Genes of Breast Cancer Patients](https://pmc.ncbi.nlm.nih.gov/articles/PMC9675926)
[nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9675926)
[https://pmc.ncbi.nlm.nih.gov › articles › PMC9675926](https://pmc.ncbi.nlm.nih.gov/articles/PMC9675926)
27. Volm, M., & Efferth, T. (2015). Prediction of Cancer Drug Resistance and Implications for Personalized Medicine. *Frontiers in Oncology*, 5, 282. [Prediction of Cancer Drug Resistance and Implications for ...National Institutes of Health \(NIH\) \(.gov\)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4681783)
[https://pmc.ncbi.nlm.nih.gov › articles › PMC4681783](https://pmc.ncbi.nlm.nih.gov/articles/PMC4681783)
28. Volm, M., & Efferth, T. (2015). Prediction of Cancer Drug Resistance and Implications for Personalized Medicine. *Frontiers*

in *Oncology*, 5, 282. [Prediction of Cancer Drug Resistance and Implications for ...National Institutes of Health \(NIH\) \(.gov\)](#)

[https://pmc.ncbi.nlm.nih.gov > articles > PMC4681783](https://pmc.ncbi.nlm.nih.gov/articles/PMC4681783)

29. Senthebane, D. A., Rowe, A., Thomford, N. E., Shipanga, H., Munro, D., M Al Mazeedi, M. A., M Almazyadi, H. A., Kallmeyer, K., Dandara, C., Pepper, M. S., Parker, M. I., & Dzobo, K. (2017). The Role of Tumor Microenvironment in Chemoresistance: To Survive, Keep Your Enemies Closer—*International Journal of Molecular Sciences*, 18(7), 1586. [The Role of Tumor Microenvironment in Chemoresistance National Institutes of Health \(NIH\) \(.gov\)](#)[https://pubmed.ncbi.nlm.nih.gov > ...](https://pubmed.ncbi.nlm.nih.gov)

30. Hirata, E., & Sahai, E. (2017). Tumor Microenvironment and Differential Responses to Therapy. *Cold Spring Harbor Perspectives in Medicine*, 7(7), a026781. [Tumor Microenvironment and Differential Responses to ...National Institutes of Health \(NIH\) \(.gov\)](#)[https://pubmed.ncbi.nlm.nih.gov > ...](https://pubmed.ncbi.nlm.nih.gov)

31. Whiteside, T. (2008). The tumour microenvironment and its role in promoting tumour growth. *Oncogene*, 27(45), 5904. The tumour [microenvironment and its role in promotintumourr ...National Institutes of Health \(NIH\)](#)

[\(.gov\)https://pmc.ncbi.nlm.nih.gov > articles > PMC3689267](https://pmc.ncbi.nlm.nih.gov/articles/PMC3689267)

32. Garg, P., Malhotra, J., Kulkarni, P., Horne, D., Salgia, R., & Singhal, S. S. (2024). Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells. *Cancers*, 16(13), 2478. [Emerging Therapeutic Strategies to Overcome Drug ... National Institutes of Health \(NIH\) \(.gov\)](#)

33. Ramos, A., Sadeghi, S., & Tabatabaeian, H. (2021). Battling Chemoresistance in Cancer: Root Causes and Strategies to

Uproot Them. *International Journal of Molecular Sciences*, 22(17), 9451. [Battling Chemoresistance in Cancer: Root Causes and](#)

...

[National Institutes of Health \(NIH\) \(.gov\)](#)

34. National Cancer Institute. (2025, October 3). Definition of drug resistance. NCI Dictionary of Cancer Terms. Retrieved from <https://www.cancer.gov>

35. [Radiation Therapy for Cancer: How Does It Work?](#)

36. Lin, X., Kong, D., & Chen, S. (2022). Editorial: Chemo-Radiation-Resistance in Cancer Therapy. *Frontiers in Pharmacology*, 13, 904063. [https://pmc.ncbi.nlm.nih.gov > articles > PMC91599](https://pmc.ncbi.nlm.nih.gov/articles/PMC91599)

37. Shuel, S. L. (2022). Targeted cancer therapies: Clinical pearls for primary care. *Canadian Family Physician*, 68(7), 515.

[Targeted cancer therapies: Clinical pearls for primary care](#)

38. Shuel, S. L. (2022). Targeted cancer therapies: Clinical pearls for primary care. *Canadian Family Physician*, 68(7), 515. <https://doi.org/10.46747/cfp.6807515>

39. Davodabadi, F., Sajjadi, S. F., Sarhadi, M., Mirghasemi, S., Nadali Hezaveh, M., Khosravi, S., Kamali Andani, M., Cordani, M., Basiri, M., & Ghavami, S. (2023). Cancer chemotherapy resistance: Mechanisms and recent breakthrough in targeted drug delivery. *European Journal of Pharmacology*, 958, 176013. <https://doi.org/10.1016/j.ejphar.2023.176013>

40. Mokhtari, R. B., Homayouni, T. S., Baluch, N., Morgatskaya, E., Kumar, S., Das, B., & Yeger, H. (2017). Combination therapy in combating cancer. *Oncotarget*, 8(23), 38022. <https://doi.org/10.18632/oncotarget.16723>

41. <https://www.merckmanuals.com/en-ca/home/cancer/prevention-and-treatment-of-cancer/combination-cancer-therapy>

42. Rabaan, A. A., AlSaihati, H., Bukhamsin, R., Bakhrebah, M. A., Nassar, M. S., Alsaleh, A. A., Alhashem, Y. N., Bukhamseen, A. Y., Al-Ruhimy, K., Alotaibi, M., Alsubki, R. A., Alahmed, H. E., Al-Abdulhadi, S., Alhashem, F. A., Alqatari, A. A., Alsayyah, A., Farahat, R. A., Abdulal, R. H., Al-Ahmed, A. H., . . . Mohapatra, R. K. (2023). Application of CRISPR/Cas9 Technology in Cancer Treatment: A Future Direction. *Current Oncology*, 30(2), 1954.

<https://doi.org/10.3390/curroncol30020152>

43. [**Antithymocyte Globulin - LiverTox - NCBI Bookshelf**](#)

44. Rabaan, A. A., AlSaihati, H., Bukhamsin, R., Bakhrebah, M. A., Nassar, M. S., Alsaleh, A. A., Alhashem, Y. N., Bukhamseen, A. Y., Al-Ruhimy, K., Alotaibi, M., Alsubki, R. A., Alahmed, H. E., Al-Abdulhadi, S., Alhashem, F. A., Alqatari, A. A., Alsayyah, A., Farahat, R. A., Abdulal, R. H., Al-Ahmed, A. H., . . . Mohapatra, R. K. (2023). Application of CRISPR/Cas9 Technology in Cancer Treatment: A Future Direction. *Current Oncology*, 30(2), 1954.

<https://doi.org/10.3390/curroncol30020152>

45. Jamal-Hanjani, M., Quezada, S. A., Larkin, J., & Swanton, C. (2015). Translational Implications of Tumor Heterogeneity. *Clinical Cancer Research : An Official Journal of the American Association for Cancer Research*, 21(6), 1258.

<https://doi.org/10.1158/1078-0432.CCR-14-1429>

46. Cheng, Y. (2021). DNA Repair Pathways in Cancer Therapy and Resistance. *Frontiers in Pharmacology*, 11, 629266.

<https://doi.org/10.3389/fphar.2020.629266>

47. Bangarh, R., Saini, R. V., Saini, A. K., Singh, T., Joshi, H., Ramniwas, S., Shahwan, M., & Tuli, H. S. (2025). Dynamics of epithelial–mesenchymal plasticity driving cancer drug resistance. *Cancer Pathogenesis and Therapy*, 3(2), 120-128.

<https://doi.org/10.1016/j.cpt.2024.07.002>

48. Huang, Y., Hong, W. & Wei, X. The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis. *J Hematol Oncol* 15, 129 (2022).

<https://doi.org/10.1186/s13045-022-01347-8>

49. Duan, C., Yu, M., Xu, J., Li, B., Zhao, Y., & Kankala, R. K. (2023). Overcoming Cancer Multi-drug Resistance (MDR): Reasons, mechanisms, nanotherapeutic solutions, and challenges. *Biomedicine & Pharmacotherapy*, 162, 114643.

<https://doi.org/10.1016/j.biopha.2023.114643>

50. Huang, Y., Hong, W. & Wei, X. The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis. *J Hematol Oncol* 15, 129 (2022).

<https://doi.org/10.1186/s13045-022-01347-8>

51. Gong, Y., Fan, Z., Luo, G. et al. The role of necroptosis in cancer biology and therapy. *Mol Cancer* 18, 100 (2019).

<https://doi.org/10.1186/s12943-019-1029-8>

52 Kim, S. K., & Cho, S. W. (2022). The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment. *Frontiers in Pharmacology*, 13, 868695.

<https://doi.org/10.3389/fphar.2022.868695>

53. Liang Zhu^{1,2^}, Minlin Jiang^{1,2}, Hao Wang^{1,2}, Hui Sun², Jun Zhu², Wencheng Zhao², Qiyu Fang², Jia Yu², Peixin Chen^{1,2}, Shengyu Wu^{1,2}, Zixuan Zheng^{1,2}, Yayi He² A narrative review of tumor heterogeneity and challenges to tumor drug therapy - Zhu - Annals of Translational Medicine.

54. Liu, S., Zhang, X., Wang, W. et al. Metabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer. *Mol Cancer* 23, 261 (2024).

<https://doi.org/10.1186/s12943-024-02165-x>